Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease
Phase of Trial: Phase I/II
Latest Information Update: 10 May 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 04 May 2017 Planned End Date changed from 1 Jul 2016 to 1 Jul 2018.
- 04 May 2017 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2018.